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ABSTRACT 
Background: Peripherally inserted central catheters (PICCs) are a commonly used central 
intravenous (IV) access device, which sometimes cause severe complications. Midline catheters 
(MC) are peripheral IV access devices that may reduce the need for central lines, and hence 
central line associated blood stream infection (CLABSI). The objective of this study is to 
compare the utilization and safety of PICC and MC.  
Methods: This was a retrospective quality improvement study. Data were collected using 
electronic medical records and IV team insertion data. SAS v9.3 was used for analysis. Means 
and standard deviations were calculated to describe central tendencies and variation. Fisher’s 
Exact Tests were used to describe strength of associations between variables. 
Results: From January to May 2015, a total of 206 PICCs and 200 MCs were inserted in 367 
individual patients. There was a total of 12 individual PICCs and 39 individual MCs involved 
with complications. MCs are associated with higher rate of non-serious complications as 
compared to PICCs. However, the severe complications were not significantly different between 
PICCs and MCs (4.9% vs. 9.0%, P=0.1182). Among the 206 PICCs, four readmissions were 
related to PICC issues, while among the 200 MCs, no readmission was caused by MC issues.  
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Conclusions: The reduction of CLABSIs could be a reasonable trade off for the increased non-
severe complications associated with MCs. As technology of these devices is evolving, longer-
term data will be essential to assure safety of MCs. Additional prospective studies could more 
objectively assess the safety and efficacy of these two devices. 
Public Health Importance: A CLABSI is one of the most costly health care-associated 
infections (HAIs), and can cause prolonged hospital stays, increased costs and risk of mortality. 
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1.0  BACKGROUND 
A central line-associated bloodstream infection (CLABSI) is a serious infection which can cause 
prolonged hospital stays, increased costs and risk of mortality.1 According to the Centers for 
Disease Control and Prevention (CDC), “a CLABSI is a primary blood stream infection (BSI) in 
a patient that had a central line within the 48-hour period before the development of the BSI and 
is not bloodstream related to an infection at another site”.2, 3  It is estimated that in the United 
States 30,100 CLABSIs occur in intensive care units (ICUs) and wards of acute care facilities 
each year.1 According to a meta-analysis, CLABSIs were the most costly health care-associated 
infections (HAIs) estimated at $45,814 (95% CI, $30,919-$65,245) on a per-case basis.4  
Between 2008-2013, CLABSIs decreased by 46% in the U.S. hospitals.1 Comparing 2009 
to 2001, there was a 58% reduction of CLABSIs in American ICUs, which were estimated to be 
25,000 fewer cases.5 Various factors contributed to the decreased infections, including 
performing hand hygiene and aseptic techniques, using antimicrobial/antiseptic impregnated 
catheters and cuffs, improving education and training, and placing by IV team.2, 5-8 Increasing 
adherence to recommended best-practices for the central line insertions has also proved to be a 
good approach to CLABSI reduction.5  
A peripherally inserted central catheter (PICC) is one of the most commonly used non-
tunnelled central IV access devices, which has the advantage of ease of placement, safety, and 
cost-effectiveness compared with traditional central venous catheters (CVCs).9, 10 However, 
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PICCs are also involved with two major severe complications, including CLABSI and deep 
venous thrombosis (DVT).9, 11 Central line complications are a major cause for increased costs 
and longer hospital stay.9, 11 A midline catheter (MC) is a peripheral IV access modality which 
may reduce the need for central access (CVCs and PICCs), and as a result, the CLABSIs.12, 13 
PICCs are inserted via peripheral veins in the antecubital fossa and terminated in the 
superior vena cava leading into the right atrium.14, 15 A MC has the same insertion area as a 
PICC, but instead of entering a central vein near the heart it ends in a large peripheral vein.14, 15 
In general, PICCs can be used for long-term intravenous (IV) access for antibiotics, 
chemotherapy and total parenteral nutrition (TPN) while MCs are usually used for shorter 
duration and some limitations with the certain medications such as amiodarone.12, 14 According 
to the Michigan Appropriateness Guide for Intravenous Catheters (MAGIC), when the line 
duration was likely to be 14 or fewer days, MCs were preferred over PICCs.16 For cancer 
patients, no matter how long the line duration was, PICCs were appropriate for irritant or 
vesicant infusion.16 Prolonged hospitalization and treatment for PICC-associated infections also 
cause additional costs.12 
The objective of this study is to compare the safety and utilization of PICC and MC 
inserted at a large academic university-affiliated medical center.  
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2.0  METHODS 
This was a retrospective study conducted at a large university affiliated medical center (>500 
beds) in the state of Pennsylvania, USA. PICCs and MCs were inserted by registered nurses of 
the IV team following CDC’s guidelines. PICCs and MCs were both manufactured by Bard (605 
N. 5600 W., Salt Lake City, UT 84116, US). From January to May 2015, a total of 206 PICCs 
and 200 MCs were inserted in 367 inpatients in both ICUs and wards. Data including 
demographics, comorbidity score, length of stay (LOS), insertion location, line duration, and 
complications were collected using electronic medical records and IV team insertion data.  
2.1 MEASURE OF ADVERSE OUTCOMES 
Complications were defined as any of the following: discontinuation due to infiltration or 
phlebitis or catheter-related bloodstream infection (CR-BSI), deep venous thrombosis (DVT); 
readmission due to PICC or MC related issues; positive blood culture; and discontinuation due to 
non-patent, dislodgement, catheter fracture, leaking, pain or edema. Severe complications were 
defined as discontinuation due to infiltration, phlebitis or infection; DVT; readmission due to 
PICC or MC issue; and positive blood culture. We used the CDC’s diagnostic definition of CR-
BSI to identify infections specifically caused by PICCs and midline catheters in this study.2 
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DVTs and other complications were included when they were documented in the electronic 
medical records. 
2.2 OTHER VARIABLES MEASURED 
Demographics such as age and gender, Charlson comorbidity index (Charlson CI), length of 
hospital stay, insertion location, line duration, reason for insertion, and type of line were also 
documented in medical records. The Charlson comorbidity index was calculated by evaluating 
17 disease categories such as COPD, cerebrovascular disease, diabetes mellitus, solid tumor and 
AIDS to evaluate patient conditions.14 A high score means a severe condition. We compared the 
complications of patients with a high Charlson score and that of patients with a lower Charlson 
score in this study.   
2.3 DATA COLLECTION AND STATISTICAL ANALYSIS 
Demographics, line insertion and removal information, and complications were collected from 
PowerChart medical record. ICD-9 code and length of hospitalization were collected through 
McKesson and Theradoc medical records. 
The statistical package SAS v9.3 was used for analysis with a two-sided significance 
level of 0.05. Mean and standard deviation were calculated to describe the central tendency and 
variation of variables. Fisher’s Exact Tests were used to describe strength of associations 
between the variables measured. 
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2.4 ETHICS 
This was a Quality Improvement (QI) study approved by the Quality Improvement of the 
University of Pittsburgh Medical Center April, 2015. 
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3.0  RESULTS 
During the study period, there was a total of 206 PICCs and 200 MCs inserted in 367 inpatients. 
185 patients only had PICCs and 172 patients only had MCs in one admission. 10 patients had 
both PICCs and MCs in one admission. 
 
Table 1. Descriptive Patient Information 
Variable PICC (185) N (%) 
Midline (172) 
N (%) Sig. 
 Gender   0.002
* 
 Male 114 (61.6) 78 (45.4)  
 Female 71 (38.4) 94 (54.7)  
 Deceased   0.145
* 
 Yes 9 (4.9) 16 (9.3)  
 No 176 (95.1) 156 (90.7)  
 ICU Stay   0.113
* 
 Yes 83 (44.9) 92 (53.5)  
 No 102 (55.1) 80 (46.5)  
 LOSa   0.350
** 
 Number 185 172  
 Mean 13.2 14.8  
 Median 9.0 10.0  
 Lower Quartile 6.0 6.0  
 Upper Quartile 18.0 19.0  
 Charlson CI   0.330
** 
 Number 185 172  
 Mean 4.8 4.5  
 Median 5.0 4.0  
 Lower Quartile 3.0 3.0  
 Upper Quartile 6.0 6.0  
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Table 1 Continued 
 Age   0.037
** 
 Number 185 172  
 Mean 59.4 62.7  
 Median 60.0 62.5  
 Lower Quartile 49.0 53.0  
 Upper Quartile 68.0 75.0  
 TotICULOSb   0.040
** 
 Number 83 92  
 Mean 10.2 7.5  
 Median 7.0 4.0  
 Lower Quartile 3.0 2.0  
 Upper Quartile 14.0 8.0   
* Based on Fisher’s Exact Test 
** Based on Kruskal-Wallis Test 
a LOS=Length of Stay 
b TotICULOS=Total Length of Stay in ICU 
The number may not add up to 100% because of the exclusion of ten patients with both 
PICCs and MCs. 
 
The age range of the 367 patients was 19–98 years old with a mean of 61 years old. The 
MC group was significantly older than the PICC group (p=0.037). Table 1 summarizes the 
descriptive information. There was no significant difference of the Charlson CI between PICC 
group and MC group with a p-value of 0.330. In addition, the length of stay (LOS) of the PICC 
group was not significantly different with that of the MC group (p=0.350). However, the total 
ICU length of stay of the PICC group was longer than that of the MC group (p=0.040). The 
distributions for gender of these two groups were significantly different with a p-value of 0.002. 
There was no significant difference in the death rates between the PICC group and the MC group 
(p=0.145). The two group patients also have the same possibility to stay in an ICU (p=0.113). 
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A total of ten positive blood cultures were observed, with five occurring in both PICCs 
and MCs (2.4% vs. 2.5%). PICCs had three Staphylococcus coagulase negative, one 
Micrococcus spp., and one Candida glabrata; while MCs had one Enterococcus faecium, two 
Escherichia coli, one Bacteroides spp, and one Candida albicans. 
 
Table 2. Complications based on individual lines 
Complications PICC Midline Sig.a 
  N (%) N (%)  
Severe Complications 
  
0.118 
Phlebitis/infection** 3 (2.9) 5 (2.5)  
DVT* 2 (1.0) 2 (1.0)  
Readmission due to line issues* 4 (1.9) 0 (0.0)  
Positive culture* 5 (2.4) 5 (2.5)  
Infiltration** 0 (0.0) 9 (4.6)  
Subtotal* 10 (4.9) 18 (9.0)  
Minor Complications   <0.001 
Pain** 0 (0.0) 3 (1.5)  
Non-patent** 3 (2.9) 17 (8.6)  
Leaking** 0 (0.0) 2 (1.0)  
Edema** 0 (0.0) 1 (0.5)  
Subtotal* 3 (1.5) 23 (11.5)  
Total Complications* 12 (5.8) 39 (19.5) <0.0001 
* 206 PICCs and 200 MCs. 
** 102 PICCs and 197 MCs. 107 (26%) of the data are missing, which would be patients 
where the line was    still in place at discharge. 
The subtotals may not add up to the total number because of lines with more than one 
complication. 
a Based on Fisher’s Exact Test 
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Figure 1 Severe Complications 
 
 
Figure 2 Total Complications 
The average PICC duration of the 206 PICCs was 20 days, with a range of 1-97 days, and 
the average MC duration of the 200 MCs was 7 days, with a range of 0-28 days (one line was 
inserted and taken out on the same day). There was a total of 12 individual PICCs and 39 
individual MCs involved with complications. Table 2, Figure 1 and Figure 2 shows the 
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complications experienced by PICC and MC patients. MCs (19.5%) were more likely to cause a 
complication compared with PICCs (5.8%), with a p-value less than 0.0001. However, the severe 
complications were not significantly different between PICCs (4.9%) and MCs (9.0%), with a p-
value of 0.118. Among the 206 PICCs, four readmissions were related to PICC issues, while 
among the 200 MCs, no readmission was caused by MC issues.  
 
Table 3. Complications matched by individual patient, admission, and line 
 PICCs 
Number of 
patients 
Number of 
admissions/patient 
Number of 
lines/admission 
Number of 
complications/line 
Total 
complications 
5 1 1 1 1*5=5 
1 1 2 1+2=3 1*3=3 
3 1 1 2 2*3=6 
1 2 1 1+2=3 1*3=3 
Total 10 -- 12 -- 17 
MCs 
Number of 
patients 
Number of 
admissions/patient 
Number of 
lines/admission 
Number of 
complications/line 
Total 
complications 
30 1 1 1 1*30=30 
5 1 1 2 2*5=10 
2 1 2 1+1=2 2*2=4 
Total 37 -- 39 -- 44 
 
Table 3 showed the complications matched by individual patient, individual admission 
and individual line. A total of 17 complications occurred in 12 individual PICCs inserted in ten 
patients. Five of the 12 PICCs were each involved with two complications. One patient 
experienced three different complications in two admissions, with one PICC for each admission. 
Another patient with two individual PICCs in one admission also experienced three 
complications. A total of 44 complications occurred in 39 individual MCs inserted in 37 patients. 
Five of the 39 MCs were each involved with two complications. Two patients each had two 
individual MCs in one admission, and they both had one complication for one MC. 
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Table 4. Complications matched by ICU Placement & Comorbidity Index 
  
  PICC MC Sig
a 
Total complications 
Placed ICU 6 22 
0.696 
Not Placed ICU 6 17 
Severe Complications 
Placed ICU 4 12 
0.243 
Not Placed ICU 6 6 
Total complications 
Charlson CI>=5 4 14 
1.000 
Charlson CI<=5 8 25 
Severe Complications 
Charlson CI>=5 4 8 
1.000 
Charlson CI<=5 6 10 
a Based on Fisher’s Exact Test  
 
We also examined complications matched by Charlson CI and ICUs placement to see the 
difference in complications between the PICC group and MC group (Table 4). The results were 
not any different than before. Among these 406 lines, 26% (107) of the discontinuation data was 
missing because these patients were discharged with the line and we did not have access to the 
follow-up information. Therefore, the complication rate might be underestimated.   
 
Table 5. Reasons for Insertion 
  PICC (206) Midline (200) Sig.a 
N (%) N (%)  
Reasons   <0.0001 
Additional Line Needed 2 (1.0) 6 (3.0)  
Long-term ABX/Meds 131 (63.6) 0 (0.0)  
Poor IV Access 73 (35.4) 194 (97.0)   
a Based on Fisher’s Exact Test 
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Figure 3 Reasons for insertion-PICCs 
 
 
Figure 4 Reasons for insertion-MC 
 
Table 5 and the pie charts (Figure 3-4) show that the reasons for insertion were 
significantly different between patients with PICCs and MCs (p=<0.0001). 63.6% of PICCs were 
inserted for long-term antibiotic or medication use, while no midline catheter was inserted for 
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this reason. 97% of midlines were inserted for poor IV access; however, this reason only 
accounted for 35.4% of PICC insertions.  
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4.0  DISCUSSION  
This study shows that patients with PICCs had a significantly lower complication rate compared 
with MCs. However, although patients with PICCs also had a lower severe complication rate, the 
difference is not significant. This result is not the same as our expectation that MCs might be a 
safer alternative device than PICCs. However, it must be noted that the study period (five 
months) and sample size (406 lines) are limited; also the PICC group (61.6% male vs. 38.4% 
female) and the MC group (45.4% male vs. 54.7% female) had different gender distribution 
(p=0.002); in addition, the MC group was older than the PICC group (p=0.037). These reasons 
may account for the better performance of PICCs and need further research to confirm.  
Most previous studies only focused on one of these two catheters and seldom compared 
the safety and utilization of PICCs and MCs. However, one study conducted at a large urban 
teaching hospital in Adelaide, South Australia included a total of 64 adult cystic fibrosis patients 
with 231 MCs and 97 PICCs.14 It found similar adverse event rates among patients with PICCs 
and MCs, 11 and 14 adverse events per 1000 catheter days, respectively.14 The infection rate for 
MCs in our study was relatively higher than that in other studies. In the cystic fibrosis study, no 
infections associated with MCs or PICCs were found.14 Another descriptive study found a 2% 
phlebitis rate among 345 patients with MC, which is similar to the 2.5% phlebitis/infection rate 
in our study.17 In our study, the positive blood culture rates of PICCs and MCs are 2.4% and 
2.5%, respectively (P<1.000). Two of the PICC positive blood cultures (2/5) were related to a 
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PICC infection, and the other three were from other sources or probable contamination. Not all 
bacteremia were related to CLABSIs, and BSIs are far more common. None of the five positive 
cultures of MCs were caused by the line or contamination, but were from other sources, such as 
faces. One recent study showed that using MCs instead of central lines reduced the CLABSI rate 
in a ventilator unit, and midline catheters did not cause any bloodstream infections.12  
Although it seems that patients with a MC were more likely to experience adverse events 
than patients with a PICC (19.5% vs 5.8%, P<0.0001), there was no significant difference 
between severe complications of these two devices (PICC: 4.9%, MC: 9.0%, P=0.118). MCs are 
associated with higher rate of non-serious complications (10.5% =(39-18)/200) as compared to 
PICCs (0.97% =(12-10)/206). In addition, once PICC patients have complications, they are more 
likely to experience severe rather than minor complications (severe/minor=10/3), while MC 
patients are more likely to encounter minor complications (severe/minor=18/23). The reduction 
of CLABSIs could be a reasonable trade of for the non-severe complications. 
Among the 200 MCs, 96 had readmissions. However, none of these readmissions was 
caused by MC issues. A total of 49 readmissions occurred among the 206 PICCs. Four 
readmissions were related to PICC issues. Compared with MCs, PICCs are more likely to cause 
readmissions (P<0.0001). Readmission can cause extra costs for patients and penalties for 
hospitals. 
Several reasons may account for the complication difference between PICC patients and 
MC patients: 
• Study period (five months) and sample size (406 lines) are limited;  
• PICC group (61.6% male vs. 38.4% female) and the MC group (45.4% male vs. 54.7% 
female) had different gender distribution (p=0.002);  
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• The MC group was older than the PICC group (p=0.037); 
• Many patients were discharged with a PICC, and they may encounter complications after 
discharge. Therefore, the complications of PICCs were underestimated. 
 
Limitations: One limitation of this study is the problem of missing data. 26% (104 PICCs 
and 3 MCs) of the line discontinuation data was missing because these lines were still in place at 
discharge, and we had difficulties getting access to the follow-up information. Incomplete 
documentation also accounts for the missing data. In this case, the complication rate might be 
underestimated. Another limitation is that the study period (January to May 2015) is relatively 
short compared with previous studies which had at least one year study periods.12, 14, 18 In 
addition, we did not report the complications as rate per 1000 catheter days, which adjusts the 
dwell times of different devices and enables more reasonable comparison among different 
studies.12, 14 
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5.0  CONCLUSION 
Based on this study, midline catheters may be a cost-efficient alternative modality to PICCs for 
non-irritating medication when the treatment is no longer than four weeks. As technology of 
these devices is evolving, longer-term data will be essential to assure safety of MCs. Additional 
prospective studies could more objectively assess the safety and efficacy of these two devices. 
The result of this study may be affected by the small sample size and short study period; 
therefore, further research with a large sample size and longer study period is needed to compare 
the safety of MCs and PICCs. We also suggest following up with patients who were discharged 
with a line to identify complication symptoms at an early stage. This can be done by 
collaboration between hospitals and other long-term healthcare facilities, using standardized 
documentation, and intense post-discharge surveillance.  
In general, the reasons for considering MCs a better alternative to PICCs are as following: 
 The reduction of CLABSIs could be a reasonable trade off for the increased non-severe 
complications caused by MCs.  
 There were fewer readmissions due to MC issues. 
 There were fewer positive blood cultures related to MC infections. 
 MCs usually terminate in a large peripheral vein and far from hearts. Therefore MCs are 
safer than PICCs in this scenario.  
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APPENDIX: PICC AND MIDLINE CATHETER DOCUMENTATION 
 
Below is the spreadsheet used for PICC and MC documentation.
  19 
  
Table 6. PICC and MC Documentation 
PatientName PatientMRN Admission Date 
Discharge 
Date LOS 
ICU 
Admission 
Date 
ICU 
Discharge 
Date 
ICU LOS Age Gender Admitting Diagnosis Deceased 
Deceased 
Date 
Charlson 
CI 
              
              
 
PatientName PatientMRN 
Unit 
Where 
Line 
Was 
Placed 
Reason 
for 
Insertion 
Insertion 
Site Gauge 
Insertion 
Date 
Discontinue 
Date 
PICC/MC 
Duration DischargedWithPICC 
Reason for 
discontinuation 
Date of 
Culture 
Culture 
source 
Pathogen 
Related 
to 
Infection 
              
              
 
PatientName PatientMRN Readmisson Num. of Additional lines  Line Type 1 Line Type 2 Line Type 3 Line Type 4 Comments DVT 
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